Agilent Technologies Inc.
This application note describes how a focused gradient is used to optimize the scale-up process from a 4.6 × 250 mm analytical column to a 50 × 243 mm preparative HPLC purification column.
Direct scale-up from analytical flow rates of 1.5 mL/min to preparative flow rates of 177 mL/min on a combined system poses several challenges: solvent delivery must be accurate at both low and high flow rates, and detection must span a wide dynamic range to cope with vastly different concentrations (1–5).
Agilent SD-1 Binary Purification System with Agilent Prep-C18 Scalar, 4.6 × 250 mm, 10 µm analytical column and Agilent Load & Lock preparative column, 50 × 243 mm, packed with 300 g of Agilent Prep-C18, 10 µm, at 1500 psi.
Formulas from the literature were used to scale-up the generic gradient profile from the analytical to preparative column (3,4). Taking dwell volume and column dead volume into consideration, the elution points of five standard compounds were determined using a linear elution gradient from 2 to 98% B within 16 min. The elution points of two adjacent peaks gave the start- and end-points of the focused gradients each with a slope of 2% B/min.
Figure 1: Generic and focused gradient applied to the standard calibration mixture and overlaid with a sample.
5 µL of sample were analyzed on the analytical column using the generic gradient profile. The two target compounds eluted within window #3, hence focused gradient #3 was used for purification. A resolution of 1.11 for the two compounds was still obtained with an injection volume of 40 µL equivalent to 18.7 mg of sample. For purification on the preparative column, the scale-up formula was used to calculate a final injection volume of 4500 µL (2.11 mg). The recovery level of the collected fractions was 85 and 89%, respectively.
The Agilent SD-1 Purification System is a combined analytical/preparative HPLC system that provides for straightforward scale-up from a 4.6 × 250 mm i.d. analytical column to a 50 × 243 mm i.d. self-packed Agilent Load & Lock column. A focused gradient facilitated increase of column load and reduced runtime and solvent consumption.
(1) J.W. Dolan, LCGCNorth Am. 24(5), 458–466 (2006).
(2) J.W. Dolan and L.R. Snyder, J. of Chromatography A 99, 21–34 (1998).
(3) D. Guillarme, D. Nguyen, S. Rudaz, and J.L. Veuthey, Eur.J. Pharm. Biopharm. 66, 475–482 (2007).
(4) D. Guillarme, D. Nguyen, S. Rudaz, and J.L. Veuthey, Eur.J. Pharm. Biopharm. 68, 430–440 (2008).
(5) L.R. Snyder, J.J. Kirkland, and J.W. Dolan, Introduction to Modern Liquid Chromatography (3rd Edition, Wiley, Hoboken, New Jersey, 2010), pp. 403–498.
(6) P. Penduff, Scale-up with the Agilent SD-1 Purification System Analytical and Preparative Runs on a Single System, Agilent publication number 5991-2012EN, 2013.
Agilent Technologies Inc.
5301 Stevens Creek Blvd., Santa Clara, CA 95051
tel. (800) 227-9770 (Directory)
Website: www.agilent.com/chem/purifyyourway
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.